Super Current Affairs

Science & Tech

AI and Machine Learning to Accelerate Drug Discovery, Reduce Time and Cost: CDRI Scientist

1 November 20262 min1 source4 questionsStory 34 of 61

For Prelims: Artificial Intelligence (AI), Machine Learning (ML), Molecular Docking, Convolutional Neural Network (CNN)

For Mains: In silico drug discovery, Computational biology, AI in healthcare

Source:HindustanHindustan

Why in the news?

AI and machine learning are being leveraged to predict which molecules can target disease-related proteins, potentially slashing the time and cost of drug discovery. The approach uses molecular docking analysis and convolutional neural networks to screen and optimize drug candidates, moving from traditional lab-based testing to computational prediction.

Summary

  • AI and ML can predict molecule-protein interactions, reducing the need for extensive laboratory testing of thousands of chemical compounds.
  • Two primary techniques are used: molecular docking analysis and convolutional neural networks (CNNs) for 3D molecular structure analysis.
  • This computational approach aims to lower both the time and cost of drug discovery, a key goal for pharmaceutical research.

Background

Traditional drug discovery is a lengthy and expensive process, often taking over a decade and costing billions of rupees. It involves screening thousands of chemical compounds in the lab to find a molecule that effectively targets a disease. AI and ML offer a paradigm shift by performing initial screening in silico (on computers), drastically reducing the number of compounds that need physical testing.

Key Analysis and Impact

The two techniques highlighted are molecular docking (analyzing how a molecule fits into a protein's active site) and convolutional neural networks (analyzing 3D molecular structures from multiple angles). These methods can rapidly filter out ineffective molecules and even suggest structural modifications to improve efficacy. This has the potential to accelerate the development of new drugs for diseases like cancer, diabetes, and infectious diseases, and reduce the cost of bringing a drug to market.

Way Forward

The integration of AI into drug discovery is still evolving. Key challenges include the need for high-quality training data, validation of AI predictions in real-world lab settings, and regulatory frameworks for AI-designed drugs. However, initiatives like HABIT-2026, which foster collaboration between institutions (CDRI, MNNIT, IIT-BHU, etc.) and between disciplines (biotechnology, computer science), are crucial for advancing this field in India.

Background GK

Textbook concepts you need to understand this news

Artificial Intelligence (AI)
The simulation of human intelligence processes by machines, especially computer systems. These processes include learning, reasoning, and self-correction.
Machine Learning (ML)
A subset of AI that enables systems to learn and improve from experience without being explicitly programmed. It uses algorithms to analyze data, identify patterns, and make decisions.
Molecular Docking
A computational technique that predicts the preferred orientation of one molecule (a ligand) when bound to another (a protein) to form a stable complex. It is used to predict the strength and nature of the binding.
Convolutional Neural Network (CNN)
A class of deep neural networks, most commonly applied to analyze visual imagery. In drug discovery, CNNs can analyze the 3D structure of molecules to predict their properties.

Facts to remember

Tap a card to see the answer. Try to recall it first.

How exams will ask this

  • Data: AI/ML can reduce time and cost of drug discovery by predicting molecule-protein interactions.

Common mistake:

Students may confuse the two techniques: molecular docking (binding analysis) vs. CNNs (3D structure analysis). Also, they might swap CDRI with another research institute (e.g., CCMB, IICT).

Write these in mains answers

  • In silico drug discovery, Computational biology, AI in healthcare

Stuck? Get it in one tap

Practice questions

Pick an answer, then read the explanation.

  1. Q1Easy

    With which institute is the scientist advocating for AI/ML in drug discovery associated?

  2. Q2Hard

    Consider the following statements regarding AI-enabled drug discovery and HABIT-2026:

    1. 1.The Central Drug Research Institute (CDRI) is located in Kanpur.
    2. 2.HABIT-2026 was organized by the Department of Biotechnology.
    3. 3.The Young Scientist Award was given to Amarjeet Yadav of MNNIT.

    Which of the statements given above is/are correct?

  3. Q3Medium

    Who received the prestigious Young Scientist Award at the HABIT-2026 conference?

  4. Q4Medium

    What is the primary objective of using AI and Machine Learning in drug discovery?

Frequently asked questions

1. How can AI and machine learning accelerate drug discovery?

AI and ML can predict which molecules will bind to disease-related proteins, reducing the need for extensive laboratory testing of thousands of chemical compounds, thereby saving time and cost.

2. Which institute's scientist made this statement about AI and drug discovery?

The statement was made by Dr. Mohammad Imran Siddiqui, a scientist at the Central Drug Research Institute (CDRI), Lucknow.

3. What is the HABIT-2026 conference?

HABIT-2026 is an international conference organized by the Department of Biotechnology (DBT) at MNNIT, focusing on health, agriculture, food security, and environmental challenges.

4. Who received the Young Scientist Award at HABIT-2026?

Amarjeet Yadav from IIT (BHU) received the prestigious Young Scientist Award for his research at the conference.

All sources

Stories from the last 30 days on the same topic, state or exams

EnvironmentBiharUttar PradeshDelhiAndhra PradeshAssamChhattisgarhGujaratKarnatakaMadhya PradeshMaharashtraOdishaRajasthanWest BengalUPSC: Important

Bharat RE 2026: 130+ countries, 9 partners, 13 Indian states

  • Nodal Ministry: Prime Minister's Office (event inaugurated by PM)
  • Venue: Bharat Mandapam, New Delhi
Background GK: International Solar Alliance (ISA)Nodal: Prime Minister's OfficeDon't make this mistake!
4 questions · 2 minPIB
PolityMadhya PradeshMPPSC: Very important

MP: 50% subsidy for private industrial parks, new MSME-IDC formed

  • Subsidy for private industrial parks: 50% of development cost, max ₹50 lakh/hectare
  • New company for MSME: Madhya Pradesh MSME Industrial Development Company (MSME-IDC)
Background GK: MSME (Micro, Small and Medium Enterprises)Nodal: Government of Madhya PradeshDon't make this mistake!
4 questions · 3 minDainik Bhaskar